Schedule 13D ownership disclosure
Summit Therapeutics plc
Security class unavailable · CUSIP: 86627R102
Event date: 2020-06-12
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 4.0600%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000919574-20-004158
- Form type
- SC 13D
- Filer
- LANSDOWNE PARTNERS
- CIK
- CIK 1608485
- Filed
- Jun 17, 2020
- Reporting period
- Jun 12, 2020
- Description
- Schedule 13D beneficial ownership